Integrating Patient‐Centric Clinical Pharmacology and MID3 to Advance Biologic Development in Immune‐Mediated Inflammatory Diseases

{"Advances":[0],"in":[1,85,128],"biologics":[2],"and":[3,7,22,35,48,59,67,105,108,113,135],"model-informed":[4],"drug":[5],"discovery":[6],"development":[8,64],"(MID3)":[9],"are":[10,116],"transforming":[11],"the":[12,71,81,86,118],"treatment":[13,53],"of":[14,65,88,121],"immune-mediated":[15],"inflammatory":[16,129],"diseases":[17],"(IMIDs).":[18],"By":[19],"integrating":[20],"pharmacokinetics":[21],"pharmacodynamics,":[23],"MID3":[24,96,112],"enables":[25],"mechanism-based,":[26],"patient-centered":[27],"strategies":[28],"to":[29],"optimize":[30],"therapies,":[31,124],"strengthen":[32],"benefit-risk":[33],"assessment,":[34],"advance":[36],"precision":[37,114],"medicine.":[38,61],"Innovations":[39],"such":[40],"as":[41],"cytokine":[42],"inhibitors,":[43],"bispecific":[44],"antibodies,":[45],"antibody-drug":[46],"conjugates,":[47],"mRNA":[49],"therapies":[50],"have":[51],"expanded":[52],"options":[54],"across":[55],"dermatology,":[56],"rheumatology,":[57],"gastroenterology,":[58],"respiratory":[60],"The":[62],"rapid":[63],"JAK-":[66],"interleukin-targeted":[68],"agents":[69],"underscores":[70],"shift":[72],"toward":[73],"individualized,":[74],"mechanistically":[75],"driven":[76],"therapies.":[77],"At":[78],"ASCPT":[79],"2025,":[80],"session":[82],"\\"Transformative":[83],"Advancements":[84],"Treatment":[87],"IMIDs:":[89],"Integrating":[90],"Patient-Centric":[91],"Clinical":[92],"Pharmacology":[93],"with":[94,125],"Translational":[95],"for":[97],"Biologics\\"":[98],"brought":[99],"together":[100],"experts":[101],"from":[102],"academia,":[103],"industry,":[104],"regulatory":[106],"agencies":[107],"emphasized":[109],"how":[110],"translational":[111],"pharmacology":[115],"accelerating":[117],"next":[119],"generation":[120],"patient-tailored":[122],"biologic":[123],"case":[126],"studies":[127],"bowel":[130],"disease,":[131],"systemic":[132],"lupus":[133],"erythematosus,":[134],"rheumatology.":[136]}

Authors

Institutions

Publication Details

Journal
Clinical Pharmacology & Therapeutics
Published
2026-09-03
DOI
https://doi.org/10.1002/cpt.70471
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Integrating Patient‐Centric Clinical Pharmacology and MID3 to Advance Biologic Development in Immune‐Mediated Inflammatory Diseases

Brian Cicali, Sihem Ait‐Oudhia, Dipak S. Pisal, Li Zhang
Clinical Pharmacology & Therapeutics
Rheumatoid Arthritis Research and Therapies
article

Integrating Patient‐Centric Clinical Pharmacology and MID3 to Advance Biologic Development in Immune‐Mediated Inflammatory Diseases

Brian Cicali, Sihem Ait‐Oudhia, Dipak S. Pisal, Li Zhang
article en

Abstract

Advances in biologics and model-informed drug discovery and development (MID3) are transforming the treatment of immune-mediated inflammatory diseases (IMIDs). By integrating pharmacokinetics and pharmacodynamics, MID3 enables mechanism-based, patient-centered strategies to optimize therapies, strengthen benefit-risk assessment, and advance precision medicine. Innovations such as cytokine inhibitors, bispecific antibodies, antibody-drug conjugates, and mRNA therapies have expanded treatment options across dermatology, rheumatology, gastroenterology, and respiratory medicine. The rapid development of JAK- and interleukin-targeted agents underscores the shift toward individualized, mechanistically driven therapies. At ASCPT 2025, the session "Transformative Advancements in the Treatment of IMIDs: Integrating Patient-Centric Clinical Pharmacology with Translational MID3 for Biologics" brought together experts from academia, industry, and regulatory agencies and emphasized how translational MID3 and precision pharmacology are accelerating the next generation of patient-tailored biologic therapies, with case studies in inflammatory bowel disease, systemic lupus erythematosus, and rheumatology.

Clinical Pharmacology & Therapeutics
University of Central Florida (US), Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Center for Drug Evaluation and Research (US), Daiichi Sankyo (United States) (US)
Openalex Percentile: Top 9%
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.